31 May 2017 in Proceedings of the National Academy of Sciences
Significance: The human fungal pathogen Candida albicans uses the Target of Rapamycin (TOR) signaling pathway to contend with varying host environments and thereby, regulate cell growth. Seeking unknown components of the C. albicans TOR pathway, we identified a phosphate importer, Pho84, and its molecular link to Target of Rapamycin complex 1 (TORC1). Because phosphorus is a critical element for anabolic processes, like DNA replication, ribosome biogenesis, translation, and membrane biosynthesis, TORC1 monitors its availability in regulating these processes. By depleting the central kinase in the TORC1 pathway, we showed that TORC1 signaling modulates regulation of phosphate acquisition. A Food and Drug Administration-approved small molecule inhibitor of Pho84 inhibits TORC1 signaling and potentiates the activity of the antifungals amphotericin B and micafungin.
2 February 2015 in PLOS Genetics
SISPARTAC trial investigators
SPARTAC trial investigators
+7
The existence of viral variants that escape from the selection pressures imposed by cytotoxic T-lymphocytes (CTLs) in HIV-1 infection is well documented, but it is unclear when they arise, with reported measures of the time to escape in individuals ranging from days to years. A study of participants enrolled in the SPARTAC (Short Pulse Anti-Retroviral Therapy at HIV Seroconversion) clinical trial allowed direct observation of the evolution of CTL escape variants in 125 adults with primary HIV-1 infection observed for up to three years. Patient HLA-type, longitudinal CD8+ T-cell responses measured by IFN-γ ELISpot and longitudinal HIV-1 gag, pol, and nef sequence data were used to study the timing and prevalence of CTL escape in the participants whilst untreated. Results showed that sequence variation within CTL epitopes at the first time point (within six months of the estimated date of seroconversion) was consistent with most mutations being transmitted in the infecting viral strain rather than with escape arising within the first few weeks of infection. Escape arose throughout the first three years of infection, but slowly and steadily. Approximately one third of patients did not drive any new escape in an HLA-restricted epitope in just under two years. Patients driving several escape mutations during these two years were rare and the median and modal numbers of new escape events in each patient were one and zero respectively. Survival analysis of time to escape found that possession of a protective HLA type significantly reduced time to first escape in a patient (p = 0.01), and epitopes escaped faster in the face of a measurable CD8+ ELISpot response (p = 0.001). However, even in an HLA matched host who mounted a measurable, specific, CD8+ response the average time before the targeted epitope evolved an escape mutation was longer than two years. The cytotoxic T-lymphocyte (CTL) arm of the immune response is thought to play a significant role in the control of HIV-1 infection. Mutations within the HIV-1 genome allow the virus to escape recognition by CTLs and so evade the immune response. These escape mutations have been well documented but observed waiting times to escape within an individual have ranged from days to years. Many studies describing CTL escape have taken a detailed look at a few patients. Our analysis is based on a cohort of 125 clinical trial participants with immunologic and viral sequence data taken at regular longitudinal time points within the first few years of infection. Results suggested that the majority of CTL-related mutations present early in infection had been transmitted in the infecting viral strain as opposed to arising in the new host due to selection pressure imposed by CTLs. Whilst the prevalence of CTL escape mutations in the dataset was high, the incidence of new escape was relatively low; around one third of patients did not drive an escape within the first two years. Patients possessing a ‘protective’ HLA genotype had a significantly shorter waiting time to first escape than those without.
27 December 2017 in mSphere
Candida albicans is the major fungal pathogen of humans and is responsible for a wide range of infections, including life-threatening systemic infections in susceptible hosts. Target of rapamycin complex 1 (TORC1) is an essential regulator of metabolism in this fungus, and components of this complex are under increased investigation as targets for new antifungal drugs. The present study characterized the role of GTR1 , encoding a putative GTPase, in TORC1 activation. This study shows that GTR1 encodes a protein required for activation of TORC1 activity in response to amino acids and regulation of nitrogen starvation responses. GTR1 mutants show increased cell-cell adhesion and biofilm formation and increased expression of genes involved in these processes. This study demonstrates that starvation responses and biofilm formation are coregulated by GTR1 and suggests that these responses are linked to compete with the microbiome for space and nutrients.
15 November 2010 in The Journal of Infectious Diseases
A xenotropic murine leukemia virus-related virus (XMRV) has recently been reported in association with prostate cancer and chronic fatigue syndrome,
24 June 2020 in Journal of Clinical Microbiology
Mycobacterium abscessus complex (MABC) are multidrug resistant nontuberculous mycobacteria and cause opportunistic pulmonary infections in individuals with cystic fibrosis (CF). In this study, genomic analysis of MABC was performed to gain greater insights into the epidemiology of circulating strains in Ireland. Whole genome sequencing (WGS) was performed on 70 MABC isolates that had been referred to the Irish Mycobacteria Reference Laboratory between 2006 and 2017 across nine Irish healthcare centres. MABC comprised of 52 isolates from 27 CF patients and 18 isolates from 10 non-CF patients. WGS identified 57 (81.4%) as M. abscessus subsp. abscessus (MAB), 10 (14.3%) as M. abscessus subsp. massiliense (MMAS) and 3 (4.3%) as M. abscessus subsp. bolletii (MBOL). Forty-nine isolates (94%) from 25 CF patients were identified as MAB whereas 3 (6%) isolates from 2 CF patients were identified as MMAS. Among non-CF patients, 44% (8/18) were identified as MAB, 39% (7/18) as MMAS and 17% (3/18) as MBOL. WGS detected two clusters of closely related MAB that included isolates from different CF centres. There was greater genomic diversity of MABC among non-CF compared to CF patients. Although WGS failed to show direct evidence of patient to patient transmission among CF patients, there was a predominance of two different strains of MAB. Furthermore, some MABC were closely related to global strains suggesting their international spread. Future prospective real-time epidemiological and clinical data along with contemporary MABC sequence analysis may elucidate sources and routes of transmission among patients infected with MABC.